AlphaStocks
5.5
Consider Buy

ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Health Care / Health Care Equipment

S&P 500

$95.85

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#378out of 1123 in Health Care

Is ZIMMER BIOMET HOLDINGS, INC. a Good Investment in 2026?

ZIMMER BIOMET HOLDINGS, INC. (ZBH) scores 5.5 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates ZIMMER BIOMET HOLDINGS, INC. as Strong (Top 25% (rank 11%)). The Lynch model is the least favorable, rating it Neutral. ZIMMER BIOMET HOLDINGS, INC. currently trades above its estimated fair value of $95, suggesting limited upside at current prices. ZIMMER BIOMET HOLDINGS, INC. ranks #378 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E27.0ROE5.5Market Cap19BDiv Yield1.0

Estimated Fair Value

$94.681% above

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

28% above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Strong

Top 25% (rank 11%)

Frequently Asked Questions

Is ZIMMER BIOMET HOLDINGS, INC. (ZBH) a good investment?
Based on AlphaStocks' composite analysis, ZIMMER BIOMET HOLDINGS, INC. (ZBH) scores 5.5 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading near estimated fair value.
What is ZIMMER BIOMET HOLDINGS, INC.'s Piotroski F-Score?
ZIMMER BIOMET HOLDINGS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ZBH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $95, ZBH appears overvalued. The stock currently trades 1% above its estimated fair value. Trading near estimated fair value.
How does ZBH compare to other Health Care stocks?
ZIMMER BIOMET HOLDINGS, INC. ranks #378 out of 1123 stocks in the Health Care sector, placing it in the top 34% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about ZBH?
AlphaStocks evaluates ZBH using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 5.5/10.

Similar Stocks

PARRBFAMNTAP

Compare ZBH with

ZBH vs PARRZBH vs BFAMZBH vs NTAP

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer